Research Topics
Species | E D HsiSummaryAffiliation: Cleveland Clinic Foundation Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratoryE D Hsi
Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Arch Pathol Lab Med 125:289-94. 2001..Issues relating to regulatory developments, antibody selection, staining optimization, and test validation are addressed...
Pathologic and molecular genetic features of chronic lymphocytic leukemiaEric D Hsi
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Semin Oncol 39:74-9. 2012..Here, we will review the morphologic, immunophenotypic, and molecular genetic features of CLL and touch upon the concept of monoclonal B-cell lymphocytosis...
Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patientsAnjali S Advani
Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, The Cleveland Clinic, Cleveland, OH, USA
BMC Cancer 10:387. 2010....- Update in the pathologic features of mature B-cell and T/NK-cell leukemiasEric D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Semin Diagn Pathol 20:180-95. 2003..This in turn provides better information for clinicians to select proper therapy and determine prognosis. The characteristic pathologic features of these disorders are reviewed... - Detection of bcl-2/J(H) translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American PathologistEric D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Arch Pathol Lab Med 126:902-8. 2002.... - A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differencesEric D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Arch Pathol Lab Med 128:863-8. 2004..The clinical significance of this practice is not known... - Pathology of primary cutaneous B-cell lymphomas: diagnosis and classificationEric D Hsi
Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44195, USA
Clin Lymphoma 5:89-97. 2004..This review will focus on the features of primary cutaneous B-cell lymphomas, compare and contrast areas of discordance between the WHO and EORTC systems, and outline areas for further investigation... - Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironmentEric D Hsi
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA
Leuk Lymphoma 49:1668-80. 2008..This manuscript reviews recent advances in our understanding of the pathobiology of cHL with an emphasis on biologic prognostic markers... - The leukemias of mature lymphocytesEric D Hsi
Section of Hematopathology, Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Hematol Oncol Clin North Am 23:843-71. 2009..In this article, the major clinical, morphologic, phenotypic, and molecular genetic features of the mature B- and T-cell leukemias are reviewed, and differential diagnostic considerations are discussed... - Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science studyEric D Hsi
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Leuk Lymphoma 49:2081-90. 2008..High Ki67 (>35%) is an important independent prognostic marker in aggressively treated MCL in the rituximab era. PIM1 expression predicts poor outcome and, given its potential role as a therapeutic target, deserves further study... - Towards a molecular classification of hematolymphoid neoplasms: where are we now? Where are we going?E D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
J Histochem Cytochem 49:1323-4. 2001..Indeed, our "view" of diseases now includes a rudimentary understanding of the molecular genetic abnormalities present in the cells we study under the microscope... - Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistryE D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
Adv Anat Pathol 8:218-39. 2001..The following is a review of the current state of immunophenotyping for lymphoid neoplasms in fixed tissues... - Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemiaEric D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Br J Haematol 120:1017-25. 2003..Prospective trials are required to determine more precisely the prognostic significance of absolute expression levels in fresh CLL cells... - Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphomaS Yegappan
Department of Clinical Pathology, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
Mod Pathol 14:1147-56. 2001..Cutaneous manifestations of AL are common; however, it appears to be a systemic lymphoma. Although often fatal, patients with AL who are diagnosed early and treated with chemotherapy may achieve remission... - Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypicallyJ L Frater
Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, OH 44106, USA
Am J Clin Pathol 116:655-64. 2001..aCLL can be distinguished from typical CLL morphologically, clinically, and immunophenotypically. Atypical morphologic features in CLL seem to be a marker of aggressive clinical behavior... - Follicular lymphoma with marginal zone differentiation: microdissection demonstrates the t(14;18) in both the follicular and marginal zone componentsS Yegappan
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Mod Pathol 14:191-6. 2001.... - Use of novel t(11;14) and t(14;18) dual-fusion fluorescence in situ hybridization probes in the differential diagnosis of lymphomas of small lymphocytesJ L Frater
Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
Diagn Mol Pathol 10:214-22. 2001..FISH can be performed successfully on archival single-cell preparations (touch preparations or gravity preparations) when fresh tissue is unavailable. No discordant or false-positive cases were identified... - Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular featuresI Mirza
Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Clin Oncol 20:647-55. 2002..It remains to be seen whether, on longer follow-up, there is any clinical difference in cases with and without t(14;18)(q32;q21)... - Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experienceP Ramalingam
Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
Mod Pathol 15:647-56. 2002..Although the incidence is low, careful early monitoring of lung transplantation patients is warranted because of the poor prognosis of patients developing this complication... - Evaluation of a new paraffin-reactive CD7 T-cell deletion marker and a polymerase chain reaction-based T-cell receptor gene rearrangement assay: implications for diagnosis of mycosis fungoides in community clinical practiceA Ormsby
Department of Anatomic Pathology and Dermatology, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
J Am Acad Dermatol 45:405-13. 2001..CONCLUSION: In the diagnosis of MF, detection of CD7 deletion and monoclonal TCR rearrangements can be successfully performed in a cost-effective, timely fashion using routine formalin-fixed paraffin-embedded biopsy specimens... - Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myelomaMohamad A Hussein
Cleveland Clinic Myeloma Research Program, Cleveland Clinic Foundation, OH 44195, USA
Mayo Clin Proc 81:889-95. 2006..To evaluate the efficacy and safety of adding thalidomide to the pegylated liposomal doxorubicin, vincristine, and decreased-frequency dexamethasone (DVd) regimen for multiple myeloma... - Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimenS D Smith
Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44195, USA
Bone Marrow Transplant 40:239-43. 2007..Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed... - Is there a role for folate determinations in current clinical practice in the USA?T Latif
Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Clin Lab Haematol 26:379-83. 2004..We conclude that determination of serum folate level infrequently led to appropriate folate replacement therapy. Moreover, even when suspected, true folic acid deficiency is rare and clinical indications are not helpful in diagnosis... - A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemiaAnjali S Advani
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA
Leuk Res 34:1622-6. 2010..The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective... - Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AMLAnjali S Advani
Taussig Cancer Center, Leukemia Program, The Cleveland Clinic CCF, Cleveland, OH 44195, USA
Leuk Res 32:913-8. 2008..Whether inhibiting c-kit in patients with AML will alter prognosis is the basis of ongoing clinical trials... - A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patientsMohamad A Hussein
Myeloma Research Program, Cleveland Clinic Taussig Center, Cleveland, Ohio 44195, USA
Cancer 95:2160-8. 2002..This Phase II study evaluates combination pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone in MM patients... - OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemiaAnjali S Advani
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
Leuk Lymphoma 51:606-12. 2010..10, p = 0.036) and a trend toward a worse OS (HR 1.10, p = 0.063). OCT-2 may act as a cell survival factor in AML by mediating expression of downstream targets, such as BCL-2. These results will need to be validated prospectively... - Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group StudyJ W Sweetenham
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
Ann Oncol 21:1196-202. 2010..The purpose was to examine the prognostic impact of features of tumor cells and immune microenvironment in patients with follicular lymphoma treated with and without anti-CD20 monoclonal antibody therapy... - Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphismK A Blum
Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
Ann Oncol 21:2246-54. 2010.... - Phosphoproteins and the dawn of functional phenotypingJ Bodo
Department of Clinical Pathology, Cleveland Clinic, OH 44195, USA
Pathobiology 78:115-21. 2011..However, phosphoproteins are extremely labile, a likely explanation for inconsistent or contradictory reports. Thus, the development of new paradigms for tissue handling, immunostaining, and quality control are needed... - Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosisSarah L Ondrejka
Department of Clinical Pathology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Haematologica 96:1121-7. 2011..We report a series of leukemic phase mantle cell lymphomas with a non-progressive or slowly progressive course... - The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeuticsWouter Korver
Nuvelo, Inc, San Carlos, CA, USA
Br J Haematol 137:307-18. 2007..Taken together, these results demonstrate NTB-A as a potential new target for immunotherapy of leukaemia and lymphomas... - Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 casesThomas A Hembury
Department of Clinical Pathology, Cleveland Clinic Foundation, OH 44195, USA
Am J Clin Pathol 117:574-80. 2002..We conclude that primary cutaneous DLBCL usually occurs in elderly patients with a male predominance. Recurrences are common, but death of disease is rare... - Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphomaXiuyan Xie
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Mod Pathol 21:653-9. 2008..Characterizing PCLBCLs with markers of B-cell maturation stage is a useful framework for studying, classifying, and clinically stratifying these lymphomas... - Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturationSarah E Gibson
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Am J Clin Pathol 126:916-24. 2006..Although OCT-2 and BOB.1 were not associated with PAX5 expression, we report expression of OCT-2 in AML with myelomonocytic/monocytic maturation and BOB.1 in normal hematopoietic elements... - Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survivalYasodha Natkunam
Department of Pathology, Stanford University School of Medicine, CA, USA
Blood 109:298-305. 2007..The association with improved OS in univariate but not multivariate analysis suggests that HGAL expression is related to known clinical parameters of improved survival... - The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expressionTodd W Kelley
Department of Clinical Pathology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
Am J Clin Pathol 128:958-65. 2007..This demonstrates the importance of evaluating tumor cell markers and the tumor immune infiltrate when considering biologic prognostic markers in cHL... - TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stageMarco Herling
Department of Hematopathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Am J Surg Pathol 31:1123-9. 2007..Therefore, TCL1 expression can be used diagnostically as an indicator of the differentiation stage of a given B-cell tumor... - MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosisEric D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Am J Clin Pathol 125:776-82. 2006..Stage showed borderline significance in OS (P = .08). MAL expression seems to identify a subset of cHL with an adverse outcome and provides additional evidence for a link between cHL and MLBL... - High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlatiRaymond Lai
Leuk Lymphoma 49:1202-5. 2008 - Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcomeStephen J Sup
Department of Clinical Pathology, L-11, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH, USA
J Clin Oncol 23:3773-9. 2005..001). CONCLUSION: Expression of bcl-2 in CHL is a useful, independent prognostic marker and can be used in association with clinical parameters to identify newly diagnosed patients with a good, intermediate, or poor prognosis... - Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Blood 107:4207-13. 2006..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation... - Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapiesXiaoxian Zhao
Department of Clinical Pathology, United States
Leuk Res 32:275-85. 2008..The discovery of apoptotic pathways that can be manipulated by proteasome inhibition provides rationale for the combination of bortezomib and agents such as TRAIL in CHL treatment... - Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survivalJames R Cook
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Am J Clin Pathol 125:615-24. 2006..005). This report shows for the first time that cyclin D1 immunohistochemical analysis can provide prognostic information in plasma cell myeloma... - The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee StudyDavid M Dorfman
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Arch Pathol Lab Med 130:779-82. 2006..Consequently, correct identification of c-Kit expression is important for the diagnosis and treatment of GISTs... - CS1, a potential new therapeutic antibody target for the treatment of multiple myelomaEric D Hsi
Clinical Pathology, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Clin Cancer Res 14:2775-84. 2008.... - Advances in the diagnosis and classification of chronic lymphoproliferative disordersEric D Hsi
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA
Cancer Treat Res 121:145-65. 2004..Insight into the biology of these diseases also may provide new therapeutic targets in the future... - Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617FSarah E Gibson
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Hum Pathol 39:1111-4. 2008..Abnormal nuclear megakaryocytic staining for pSTAT5 expression, previously associated with the JAK2 V617F mutation, is also associated with MPL W515L, likely reflecting activation of the JAK-STAT signaling pathway... - Properties of the mantle cell and mantle cell lymphomaJohn L Frater
Department of Pathology, Northwestern Memorial Hospital, Chicago, Illinois, USA
Curr Opin Hematol 9:56-62. 2002..The authors summarize these new advances in the understanding of the biology of the mantle cell and newer ancillary techniques in the diagnosis of lymphomas arising from this cell type... - Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activationTania Zuluaga Toro
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
Br J Haematol 139:31-40. 2007..Nuclear pSTAT5 in MCs from SM reflects abnormal TK activation. We propose nuclear pSTAT5 positivity in MCs as an additional minor phenotypic criterion for diagnosis of SM in future World Health Organization classification schemes... - LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximabYasodha Natkunam
Department of Pathology, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J Clin Oncol 26:447-54. 2008..Here, we tested the prognostic impact of LMO2 protein expression in DLBCL patients treated with anthracycline-based chemotherapy with or without rituximab... - Simian virus 40 in posttransplant lymphoproliferative disordersRegis A Vilchez
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Hum Pathol 37:1130-6. 2006..These results suggest that SV40 may be associated with a small subset of PTLD cases. Additional studies are needed to determine the role of SV40 in EBV-negative PTLD... - Detection of mature T-cell leukemias by flow cytometry using anti-T-cell receptor V beta antibodiesRose C Beck
Division of Pathology and Laboratory Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
Am J Clin Pathol 120:785-94. 2003.... - Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcomaRajiv M Patel
Division of Pathology and Laboratory Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Mod Pathol 17:456-60. 2004..As such, it is an extremely useful tool for differentiating between Kaposi sarcoma and other vascular and nonvascular spindle cell lesions, which do not express human herpes virus 8 latent nuclear antigen-1... - Molecular pathology testing of tissues fixed in prefer solutionRaymond R Tubbs
Am J Surg Pathol 28:417-9. 2004 - Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosisTodd W Kelley
Department of Clinical Pathology, L11, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA
Leuk Res 28:845-50. 2004..27 fold (+/-2.57) increase in the percentage of apoptotic cells versus untreated controls. These data indicate that bortezomib has in vitro activity in CLL and support further investigations of this promising new drug... - Primary cutaneous lymphoblastic lymphoma presenting in an 8-week old infantJacqueline K Trupiano
Department of Pathology, Cleveland Clinic Foundation, OH 44195, USA
J Cutan Pathol 29:107-12. 2002..CONCLUSIONS: To our knowledge, only five other cases of sIg positive precursor B-cell LBL have been reported in the literature. This may represent the youngest reported case of primary cutaneous LBL, occurring at 8weeks of age... - Podocalyxin: a marker of blasts in acute leukemiaTodd W Kelley
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Am J Clin Pathol 124:134-42. 2005..Therefore, podocalyxin seems to complement CD34 as a useful hematopoietic blast marker. The physiologic role of podocalyxin in leukemic blasts remains unknown... - Response to Pantanowitz et al. Regarding our paper on the utility of the detection of HHV-8 LNA-1 by immunohistochemistry in the diagnosis of Kaposi's sarcomaRajiv M Patel
Mod Pathol 18:1011-2. 2005 - The correlation dimension identifies B-cell immunoglobulin light chain restriction in peripheral blood flow cytometry dataNicholas T Wongchaowart
Department of Clinical Pathology, Cleveland Clinic, Foundation, Cleveland, OH 44195, USA
Am J Clin Pathol 125:600-7. 2006..The D2 can identify LCR in peripheral blood flow cytometry data. It offers operator-independent data analysis and may be useful in objectively quantifying differences in data distribution... - t(14;18)(q32;q21) involving IGH and MALT1 is uncommon in cutaneous MALT lymphomas and primary cutaneous diffuse large B-cell lymphomasNicholas T Wongchaowart
Department of Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Cutan Pathol 33:286-92. 2006..However, the incidence of IGH/MALT1 translocations in these forms of cutaneous lymphoma remains unclear... - Diffuse large B-cell lymphoma of the stomach: assessment of microsatellite instability, allelic imbalance, and trisomy of chromosomes 3, 12, and 18Marek Skacel
Department of Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Diagn Mol Pathol 11:75-82. 2002..Because of the relatively low frequency of MSI in the high-grade B-cell lymphomas of the stomach, this feature cannot be used to reliably discriminate between the histologic types of extranodal diffuse large B-cell lymphoma... - Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphomaScott J Rodig
Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Am J Surg Pathol 31:106-12. 2007..Thus, the combined nuclear localization of c-Rel and the cellular expression of TRAF1 is a highly specific (specificity=98%) means to distinguish PMLBCL from DLBCL that is readily applicable to routine surgical pathology practice... - T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6XiaoQing Lu
Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
Mol Cell Biol 27:2166-79. 2007.... - Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activationSamer Aboudola
Department of Clinical Pathology and Laboratory Medicine, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Am J Surg Pathol 31:233-9. 2007..Phosphoprotein detection represents a new area for diagnostic pathology that exploits specific functional characteristics of cells within the context of a tissue section... - Detection of clonal IGH gene rearrangements: summary of molecular oncology surveys of the College of American PathologistsMarina N Nikiforova
Department of Pathology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
Arch Pathol Lab Med 131:185-9. 2007.... - Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901Myron S Czuczman
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Leuk Lymphoma 48:97-103. 2007..Median event-free survival was 1.2 months and median overall survival was 3 months. Due to lack of efficacy and excessive toxicity, nelarabine is not recommended as monotherapy in adult patients with CTCL and STCL at this dose schedule... - Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimicsRoger A Warnke
Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 5324, USA
Am J Clin Pathol 127:511-27. 2007.... - Clinical laboratory reports in molecular pathologyMargaret L Gulley
Department of Pathology, 913 Brinkhous Bullitt Bldg, University of North Carolina, Chapel Hill, NC 27599 7525, USA
Arch Pathol Lab Med 131:852-63. 2007..The recent introduction of array technology has added another layer of complexity involving massive parallel analysis of multiple genes, transcripts, or proteins... - Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphomaRose C Beck
Department of Clinical Pathology, Cleveland Clinic Foundation, Ohio 44195, USA
Diagn Mol Pathol 12:14-20. 2003..Automated CISH is useful in detecting light chain expression in paraffin sections and appeared superior to IHC for light chain detection in PC dyscrasias and B cell non-Hodgkin lymphomas, predominantly due to lack of background staining...
Research Grants
- Characterization of Methods for Preservation of Phosphoproteins in fixed tissuesEric Hsi; Fiscal Year: 2007..Furthermore, control material with defined relative expression levels of many PPs will result from this application and allow laboratories to assess performance of their individual assays. ..